One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume increases across its portfolio. Financial Highlights Total Revenue: Increased 9% year-over-year to $8.1 billion, compared to $7.4 billion in Q1 2024. Product Sales: Grew 11% […]
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst declining revenues compared to the previous year. Financial Highlights Revenue: The company reported total revenue of $108 million for Q1 2025, a decrease from $167 […]
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.
Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
